Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy

The dual function antibody targeting both αvβ3 and PD-L1 holds the potential to reverse immune evasion and exhibit synergistic anti-tumor effects, offering a promising therapeutic strategy for the treatment of solid tumor.